Sellas Life Sciences Group Inc (SLS) FinancialsSLSSellas Life Sciences Group Inc

Evaluating the bottom line, Sellas Life Sciences Group Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.63%, provide a clear picture of how effectively SLS converts its operational activities into shareholder value.

In the context of the broader market, SLS competes directly with industry leaders such as VCEL and VRDN. With a market capitalization of $2.42B, it holds a significant position in the sector. When comparing efficiency, SLS's gross margin of N/A stands against VCEL's 72.82% and VRDN's 100.00%. Such benchmarking helps identify whether Sellas Life Sciences Group Inc is trading at a premium or discount relative to its financial performance.

The company has reported significant net losses, with Q2 2026 net income projected at -$9.6 million, and a forward P/E ratio of 0, indicating no earnings expected in the near term. However, the current ratio is strong at 18.83, suggesting good liquidity.